The Hormonal Approach: How Estriol/Progesterone/Testosterone Cream Supports Male Sexual Function

Part I: The Hormonal Imbalance Theory of ED

A critical fact about male sexual health: erectile dysfunction is often hormonal in origin. A 2025 multicenter PubMed study involving 411 men found total and free testosterone levels are significantly associated with ED severity — total testosterone falling from a median of 7.05 ng/mL in men with normal function to 3.56 ng/mL in severe ED. All ED groups had median free testosterone below the normal minimum threshold.

For many men, ED is not primarily a blood flow problem — it is a hormone deficiency problem. Hormone deficiencies cannot be fixed with Viagra alone.

Researchers have also identified abnormal progesterone levels in men with ED. Patent literature notes that correcting progesterone and testosterone toward normal values helped most study participants obtain normal erectile function. The central premise: restoring hormonal balance rather than forcing vasodilation.

Part II: The Three Components and Their Roles

Testosterone is the fundamental male sex hormone for libido, erectile function, and sexual health. Low testosterone links to reduced desire, fewer spontaneous erections, and diminished erectile response. Topical delivery bypasses first-pass liver metabolism, providing more stable levels when applied to hairless skin (inner arms, chest, neck).

Critical safety note: topical testosterone can harm women and children who contact treated skin. Users must allow the cream to dry, cover the area, and wash hands thoroughly.

Progesterone inhibits conversion of testosterone to DHT via 5-alpha reductase (up to 10-fold reduction in DHT formation), may decrease aromatase activity preserving testosterone, and may correct progesterone deficiency observed in some men with ED.

Estriol is a weak estrogen with shorter duration than estradiol. Its role in male sexual health is less studied — inclusion appears based on theoretical hormonal balancing (modulating androgen metabolism, addressing estrogen dominance with aging, potential prostate considerations) rather than robust clinical trials specific to estriol in male ED.

• Testosterone: restores libido and baseline erectile physiology; requires medical monitoring.
• Progesterone: anti-androgen balancer — limits excessive DHT while supporting testosterone preservation.
• Estriol: least substantiated component; theoretical balancing role with limited male-specific evidence.

Part III: How This Combination Differs from Conventional ED Treatments

Part IV: Clinical Evidence

A two-year study of 20 men aged 21–88 evaluated bio-identical progesterone/testosterone cream. Patients had multiple comorbidities (hypertension, BPH, diabetes, cardiovascular disease, and more). Authors reported tremendous success correcting ED despite co-existing illness, with improvement in as little as three weeks to six months (average two to three months).

Important limitation: small sample (n=20), not placebo-controlled, reported in patent documentation rather than peer-reviewed journals — results should be considered preliminary.

A 1983 Archives of Sexual Behavior case report described a bilaterally castrated 48-year-old man on estrogen-progestin treatment who maintained satisfactory sexual behavior and normal-range erectile responses — suggesting progesterone and estrogen may support function even with minimal androgen, though authors cautioned results may not generalize.

Patent literature also cites DHT as potentially important for orgasm frequency and prevention of erectile failure, with the formulation designed to raise DHT effectively while limiting excessive prostate-driving conversion.

Part V: Proposed Benefits of This Cream

• Restoration of morning erections — a marker of physiological rather than medication-dependent function.
• Enhanced libido — testosterone directly increases desire, unlike PDE5 inhibitors.
• Treatment at the source — aims to correct hormonal deficiency rather than temporarily bypass it.
• Convenient once-daily topical application not timed to sexual activity.
• Potential prostate protection — progesterone may limit excessive testosterone-to-DHT conversion.

Part VI: Important Limitations and Cautions

• Limited rigorous data — primary evidence from a small non-peer-reviewed study and theoretical principles.
• Not FDA-approved for ED — typically compounded from specialty pharmacies.
• Testosterone risks: decreased sperm count, breast enlargement, urinary symptoms, clot risk, acne, headaches, skin irritation.
• Secondary transfer risk to women and children through skin contact requires strict precautions.
• Progesterone lowers DHT while DHT also supports sexual function — optimal balance is undefined.
• Estriol's role is the least proven of the three components.
• Not intended for primarily psychogenic ED — patent study excluded psychogenic cases.